Press Releases

2020

August 13, 2020
Verve Therapeutics to Participate in Oppenheimer’s Private Life Sciences Company Call Series
June 27, 2020
Verve Therapeutics Presents New Data in Non-Human Primates Validating Gene Editing as a Treatment Approach for Coronary Heart Disease at the ISSCR 2020 Virtual Annual Meeting
June 17, 2020
Verve Therapeutics CEO Sekar Kathiresan, M.D., to Give Keynote Presentation at the International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting
June 11, 2020
Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease
March 23, 2020
Verve Therapeutics’ CEO Sekar Kathiresan to Speak at Wall Street Journal Health Forum

2019

October 3, 2019
Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as Chief Scientific Officer
October 2, 2019
Verve Therapeutics to Present at the 2019 Jefferies Gene Therapy/Editing Summit
September 16, 2019
Verve Therapeutics Appoints Drug Delivery Expert Andrew Geall, Ph.D., to Scientific Advisory Board
May 7, 2019
Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GV

Media Contact
Gina Nugent
Ten Bridge Communications
(617) 460-3579
gina@tenbridgecommunications.com